The European Medicines Agency (EMA) announced this Thursday that it approved for the first time the commercialization of the European Union (EU) of two treatments with antibodies against coronavirus.
The regulatory body indicated that it had approved the use of a treatment from the Swiss pharmaceutical laboratory Roche, the Ronapreve, and a treatment from the South Korean laboratory Celltrion, called Regkirona.
“Ronapreve and Regkirona are the first monoclonal antibody-based drugs to be tested positively (…) against Covid-19“said the Amsterdam-based EMA.
The European Commissioner for Health, Stella Kyriakides, declared that the approval of the two drugs was an “important stage” against the disease since the EU relies so far on four vaccines.
“At a time when infections are on the rise in almost all Member States, it is comforting to see promising new treatments under development within our pharmaceutical strategy against Covid-19“he declared.
Antibodies are one of the bases of our immune system. Against a foreign element, such as a virus, our body produces them naturally to protect itself.
In these therapies, natural antibodies are selected and artificially reproduced for delivery as treatment, usually by injection.
Reference-www.eleconomista.com.mx